Abstract
Objective To investigate the combination of rosiglitazone treatment BiPAP breathing machine without clinical effect acute exacerbation of chronic obstructive pulmonary disease (AECOPD) record. Methods Choice in patients with AECOPD in our hospital from January 2013 to June 2015 80 cases, according to randomized into two groups, each 40 cases, this group of patients were enrolled after the implementation of symptomatic and supportive treatment, while the control group using US Respironics BiPAP Vision type of non-invasive ventilator support treatment, observation group using rosiglitazone in the control group on the basis of each 4mg, day 1, morning oral, two weeks of continuous treatment 1 course of treatment.Inflammatory cytokines before and after treatment were compared (TNF-α, IL-1 and hs-CRP) changes, before and after treatment antioxidant factors (SOD and MDA) changes, blood gas analysis (PO2 and PCO2) changes before and after treatment, and the results of pulmonary function (FEV1 and FEV1/FVC) changes, and statistical groups using non-invasive ventilator-assisted treatment time. Results After treatment, TNF-α, IL-1 and hs-CRP were significantly lower than before treatment (t=280.000, 37.210, 57.351, 115.772, 4.650, 26.415, P<0.05), and the post-treatment observation group, TNF-α, IL-1 and hs-CRP level is lower than the control group after treatment (t=212.132, 30.679, 33.527, P<0.05), after treatment in the observation group SOD levels higher than before treatment (t=36.829, P<0.05), low levels of MDA before treatment (t=32.000, P<0.05), and SOD treatment group was higher than that observed after treatment in the control group (t=23.382, P<0.05), MDA was lower than the control group after treatment (t=16.971, P<0.05), after treatment in the observation group PO2 higher than before treatment (t=9.609, P<0.05), PCO2 lower than before treatment (t=27.548, P<0.05), FEV1 higher than before treatment (t=41.777, P<0.05), FEV1/FVC higher than before treatment (t=33.621, P<0.05), and the treatment group was observed after treatment PO2 higher than the control group (t=6.276, P<0.05), PCO2 lower than the control group after treatment (t=9.499, P<0.05), FEV1 higher than the control group after treatment (t=16.611, P<0.05), FEV1/FVC higher than the control group after treatment (t=15.882, P<0.05). Conclusions Rosiglitazone BiPAP ventilation combined non-invasive treatment of AECOPD, can effectively inhibit the body's inflammatory response, reduce oxidative stress, improve lung ventilation and ventilatory function, shorten ventilator treatment time, worthy of attention. Key words: Rosiglitazone; Non-invasive ventilation therapy; Chronic obstructive pulmonary disease; Acute exacerbation; Clinical effect
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
